Cargando…
Lack of association between Ser(413)/Cys polymorphism of plasminogen activator inhibitor type 2 (PAI-2) and premature coronary atherosclerotic disease
Plasminogen activator inhibitor type-2 (PAI-2) is a serine protease inhibitor of the fibrinolytic system produced predominantly by the macrophages and monocytes. It has been demonstrated that fibrinolysis regulation has a great importance in the pathogenesis of atherosclerotic plaques. Thus in the c...
Autores principales: | Saffari, Babak, Jooyan, Najmeh, Bahari, Marzieh, Senemar, Sara, Yavarian, Majid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Leibniz Research Centre for Working Environment and Human Factors
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942808/ https://www.ncbi.nlm.nih.gov/pubmed/27418916 |
Ejemplares similares
-
5,10-methylene tetrahydrofolate reductase C677T gene polymorphism, homocysteine concentration and the extent of premature coronary artery disease in southern Iran
por: Senemar, Sara, et al.
Publicado: (2013) -
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994) -
PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020) -
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice
por: Umeda, Tomohiro, et al.
Publicado: (2015) -
Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)